ReviewCurrent oncology reports2022
What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.Clinical and experimental medicine · 2024Review
- COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.Cell communication and signaling : CCS · 2024Review
- COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.Frontiers in immunology · 2024Article
- Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.Annals of hematology · 2023Article
- Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection-A Single Center Survey.Medicina (Kaunas, Lithuania) · 2023Article
- The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study.Leukemia · 2023Article
- Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.Frontiers in cellular and infection microbiology · 2023Review
- COVID-19 Impact on Chronic Myeloid Leukemia Patients.Journal of personalized medicine · 2022Article
- Article
- Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19.Frontiers in oncology · 2022Article
- Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCOVID-19 is highly contagious; since it was first identified, the virus has rapidly spread to more than 100 countries and was declared a pandemic on March 11, 2020, by the World Health Organization (WHO). This disease presents several challenges when managing patients with leukemia. We review the information about chronic myeloid leukemia (CML) and COVID-19: risk factors, prognosis, and the role of tyrosine kinase inhibitors (TKIs). RECENT
findingsAt present, we find no data suggesting that patients with CML-chronic phase (CML-CP) are at higher risk of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general healthy population. TKIs had been proposed to fight the SARS-CoV-2-related disease (COVID-19). CML patients should continue receiving their TKIs if they have COVID-19 disease. The role of TKIs as protective factors against SARS-CoV-2 infection in patients with CML should be confirmed by large-scale epidemiologic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.